Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

Yuan Hung Kuo, Sheng Nan Lu, Yen Yang Chen, Kwong Ming Kee, Yi Hao Yen, Chao Hung Hung, Tsung Hui Hu, Chien Hung Chen, Jing Houng Wang*

*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

10 Scopus citations

Fingerprint

Dive into the research topics of 'Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Psychology